XBRANE.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 18:29):

Stats
Dzisiejszy wolumen	12.16M
Średni wolumen	23.77M
Kapitalizacja rynkowa	307.11M
EPS	SEK0 ( 2024-02-26 )
Następna data zysków	( SEK0 ) 2024-05-16
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-0.160
ATR14	SEK0 (0.00%)

Wolumen Korelacja

Długi: -0.14 (neutral)

Krótki: -0.14 (neutral)

Signal:(52.256) Neutral

Xbrane Biopharma AB Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Xbrane Biopharma AB Korelacja - Waluta/Towar

0.61
( weak )

0.68
( moderate )

0.00
( neutral )

-0.62
( weak negative )

Xbrane Biopharma AB Finanse

Annual	2023
Przychody:	SEK238.73M
Zysk brutto:	SEK13.96M (5.85 %)
EPS:	SEK-1.530

FY	2023
Przychody:	SEK238.73M
Zysk brutto:	SEK13.96M (5.85 %)
EPS:	SEK-1.530

FY	2022
Przychody:	SEK57.62M
Zysk brutto:	SEK41.04M (71.23 %)
EPS:	SEK-0.760

FY	2021
Przychody:	SEK0.00
Zysk brutto:	SEK0.00 (0.00 %)
EPS:	SEK-7.98

Financial Reports:

No articles found.

Xbrane Biopharma AB

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.